SRR5088820
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.400
- PROTEIN_SECRETION+0.400
- ALLOGRAFT_REJECTION+0.300
- G2M_CHECKPOINT+0.300
- HEDGEHOG_SIGNALING+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- MITOTIC_SPINDLE+0.300
- MTORC1_SIGNALING+0.300
- APICAL_SURFACE+0.200
- E2F_TARGETS+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- ADIPOGENESIS-0.300
- BILE_ACID_METABOLISM-0.200
- COAGULATION-0.200
- FATTY_ACID_METABOLISM-0.200
- KRAS_SIGNALING_DN-0.200
- MYC_TARGETS_V2-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- APICAL_JUNCTION-0.100
- ESTROGEN_RESPONSE_LATE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296088 | — | cohortMD2 | 0.780 |
| 2 | MDT-AP-3056 | Med | Medulloblastoma | 0.755 |
| 3 | TCGA-BH-A18V-01A-11R-A12D-07 | — | E | 0.744 |
| 4 | TCGA-ZF-AA5H-01A-11R-A39I-07 | — | — | 0.725 |
| 5 | TCGA-D8-A1X9-01A-12R-A157-07 | — | B | 0.723 |
| 6 | TCGA-77-A5GH-01A-11R-A27Q-07 | — | cohortSQ1 | 0.723 |
| 7 | 8828489a-e6fd-43ca-9232-e1b759d6edcf | — | — | 0.722 |
| 8 | TCGA-CU-A3KJ-01A-11R-A21D-07 | — | — | 0.719 |
| 9 | TCGA-A8-A07I-01A-11R-A00Z-07 | — | C | 0.716 |
| 10 | SAMN03290909 | — | — | 0.716 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |